investigated whether changes in renal function over a 7-year period were associated with the incidence of heart failure, myocardial infarction, stroke and peripheral artery disease during the ...

Sotagliflozin, a dual SGLT1/2 inhibitor, shows benefit specifically for reducing myocardial infarction and stroke risks. Among patients with type 2 diabetes and chronic kidney disease (CKD ...

Outcomes assessed were all-cause mortality, hospitalization for acute myocardial infarction, development of end-stage renal disease, and the occurrence of a doubling in serum creatinine from the ...

Classical symptoms of acute myocardial infarction include sudden chest pain ... obesity, chronic kidney disease, heart failure, excessive alcohol consumption, the abuse of certain drugs (such ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

with significant reductions in the individual outcomes of myocardial infarction (MI) and stroke in patients with type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors in a ...